Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Mol Cancer Res. 2016 Jul 14;14(10):1009–1018. doi: 10.1158/1541-7786.MCR-16-0184

Figure 6. PREX1 levels are regulated by ERK both transcriptionally and post-transcriptionally.

Figure 6

BRAF-mutant A375 and WM2664 cells were treated with vemurafenib or SCH772984 for 24 h and PREX1 mRNA levels were measured by Taqman qPCR using two independent probes (A,B). NRAS-mutant SK-MEL-119 and Mel224 cells were treated with trametinib or SCH772984 for 24 h, and PREX1 mRNA measured as above (C,D). Taqman analyses indicate compiled results of n=2 experiments for WM2664 and Mel224, and n=3 experiments for A375 and SK-MEL-119. To test posttranscriptional regulation, A375 cells were treated with vehicle or SCH772984 in the presence of 50 μg/ml cycloheximide, and lysates were probed by western blot for PREX1, pERK and MYC (E). Quantification of PREX1 levels using ImageJ (F) is representative of n=2 independent experiments. Data are represented as mean ± SD.